131I-IPA not checked
Telix Pharmaceuticals (Innovations) Pty Limited · TLX-101-Tx · 131I-TLX101
FollowEvery change as it happens, and a Monday email
Trials
2 active
2 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “131I-IPA: injection/solution administrated intravenously via infusion in ascending doses 18F-FET: injection/solution administrated intravenously”In the company’s words, NCT05450744 on ClinicalTrials.gov
- Tested for
- Neoplastic Disease (2 trials), Glioblastoma (2 trials), Glioblastoma (GBM), Glioblastoma Multiform, Glioblastoma Multiforme, Adult, Glioblastoma Multiforme (GBM) WHO Grade IV, Glioblastoma Multiforme
- Main trialPhase 3
- “This global clinical trial which evaluates the efficacy and safety of TLX101-Tx, an investigational radiopharmaceutical therapy, in combination with lomustine versus lomustine alone in adult patients with first recurrence of glioblastoma. TLX101-Tx delivers targeted radiation to glioblastoma cells. The trial is conducted in two parts: Part 1 assesses safety and radiation dosing; Part 2 is a randomized comparison of the combination therapy against standard care.”In the company’s words, NCT07100730 on ClinicalTrials.gov
- Other names
- TLX-101-Tx · 131I-TLX101 · 18F-FET
Other drugs for Glioblastoma
- SafusidenibNuvation Bio · Phase 3
- Cerebraca waferEverfront Biotech Co., Ltd. · Phase 2/3
- PembrolizumabMerck & Co. · Phase 3
- LAM561Laminar Pharmaceuticals · Phase 2/3
- VebreltinibBeijing Pearl Biotechnology Limited Liability Company · Phase 2/3
- NEO100Neonc Technologies, Inc. · Phase 1/2
Coming up2
- Jun 2027Phase 1 trial completes · ClinicalTrials.gov
- Jul 2028Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 16 NovCompletion date moved: 2027-07 to 2028-07 · ClinicalTrials.gov NCT07100730
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Jul 2028 | Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma | |
| Phase 1Active, not recruiting | Jun 2027 | 131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026